Hemarina announced on September 9 the publication of a paper in Scientific Reports demonstrating the anti-inflammatory and antibacterial properties of M101 for the treatment of periodontitis. This study validates the qualities of Hemarina’s technological platform, based on the M101 molecule, an “oxygen carrier” derived from the haemoglobin of the marine worm. The dental field is one of the 14 identified applications of this molecule produced to GMP standards.
Read the full interview with Franck Zal, President of Hemarina, on Biotech Info
